Yeh K C, Chremos A N, Lin J H, Constanzer M L, Kanovsky S M, Hucker H B, Antonello J, Vlasses P, Ryan J R, Williams R L
Department of Drug Metabolism, Merck Sharp & Dohme Research Laboratories, West Point, PA 19486.
Biopharm Drug Dispos. 1987 Nov-Dec;8(6):549-60. doi: 10.1002/bdd.2510080606.
Pharmacokinetics and bioavailability of famotidine, a new H2-receptor antagonist, were investigated in healthy subjects in five clinical studies. Linear pharmacokinetics were observed following either intravenous or oral administration. Plasma clearance averaged 463 ml min-1. Renal clearance averaged 310 ml min-1, which exceeded the glomerular filtration rate. Renal excretion was the major route of elimination. Urinary recovery of unchanged drug following intravenous administration was about 67 per cent. Famotidine plasma half-life was approximately 2.6 h. Oral absorption was incomplete. The bioavailability averaged 43 per cent of the dose.